Sergio E. Delgado
FDA investigator
Appears on 1 document from 2024, mostly at sites in Florida. Most often cites hepatitis C virus (HCV) “lookback” requirements (21 CFR 610.47(a)(1)).
- 1
- Documents on file
- 4.0
- Observations per 483
- 2024
- First seen
- 2024
- Most recent
What they cite most
From 4 observations- 21 CFR 610.47(a)(1)Hepatitis C virus (HCV) “lookback” requirements2
- 21 CFR 606.100(b)Standard operating procedures1
- 21 CFR 606.160(b)Records1
Activity by year
2024: 1
Where
Florida 1
Often inspects with
Is Sergio E. Delgado coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2024-10-07 | 483 Innovative Transfusion Medicine, Inc.Oct 7, 2024 · Florida | Florida | 4 |
About this profile
What does Sergio E. Delgado inspect?
Sergio E. Delgado appears on 1 document on file covering 1 site, mostly in Florida.
What do they cite most often?
21 CFR 610.47(a)(1) (hepatitis C virus (HCV) “lookback” requirements), followed by 21 CFR 606.100(b) and 21 CFR 606.160(b).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Sergio E. Delgado is dated Oct 7, 2024.